Title: FDA Gives Nod to New Diabetes Combination Tablet: Repaglinide + Metformin
|
|
To print: Select File and then Print from your browser's menu Title: FDA Gives Nod to New Diabetes Combination Tablet: Repaglinide + Metformin |
|
"FDA Gives Nod to New Diabetes Combination Tablet: Repaglinide + Metformin" NEW YORK -- June 24, 2008 -- The US Food and Drug Administration (FDA) has approved a replaglinide and metformin fixed-dose combination tablet (PrandiMet) for the treatment of type 2 diabetes. The replaglinide and metformin fixed-dose combination tablet has been approved as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes who are already treated with a meglitinide and metformin or who have inadequate glycaemic control on a meglitinide alone or metformin alone. The new agent works to control 3 abnormalities of type 2 diabetes: impaired insulin secretion, insulin resistance, and excessive hepatic glucose production. SOURCE: Novo Nordisk |
|
Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. Go back This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 2009 P\S\L Consulting Group Inc. All rights reserved. |